A leadless cardiac pacemaker showed “good safety and reliable function” during the initial six months of follow-up in the LEADLESS II study, investigators reported during a Hot Line presentation at the ESC congress 2015.
EMBARGO 30 August 2015 at 09:00 BST
STUDY NAME: The LEADLESS II trial
SESSION NAME: Hot Line II - Atrial fibrillation/Pacing
The findings, published simultaneously in the New England Journal of Medicine, suggest the device is effective and safe, and can serve as an alternative to conventional transvenous pacemakers in patients with indications for permanent pacing, said principal investigator Vivek Reddy, MD.
“Leadless cardiac pacemakers have the potential to overcome many of the complications of conventional transvenous pacemakers,” said Dr. Reddy, from Icahn School of Medicine at Mount Sinai in New York, NY, USA. “Transvenous leads are considered the Achilles’ heel of conventional pacemakers because they are particularly susceptible to complications.”
LEADLESS II was a prospective, non-randomized, pre-marketing study that included 526 patients (mean age 75.8 years) from 56 sites in 3 countries.
All patients had indications for permanent, single-chamber, ventricular pacing and were implanted non-surgically with an active fixation, rate-adaptive pacemaker using a steerable delivery catheter.
The primary effectiveness endpoint was clinically acceptable pacing capture thresholds (≤ 2.0 V at 0.4 ms) and sensing (R-wave ≥ 5.0 mV or ≥ implant value) at six months, and the primary safety endpoint was freedom from serious adverse device effects (SADEs) over the same time frame.
Among 300 subjects in the intention-to-treat primary analysis, the primary effectiveness and safety endpoints were met in 90.0% and 93.3% respectively, and effectiveness was met in 93.4% of successfully implanted patients.
There was a 6.7% rate of SADEs over 6 months, including cardiac perforation (1.3%), device dislodgement with successful percutaneous retrieval (1.7%), and capture threshold elevation requiring percutaneous retrieval and placement of a new leadless pacemaker (1.3%). There were no device-related infections or chronic electrical failure.
Among the five device dislodgements observed, device embolisation to the lung occurred in three subjects and migration to the right femoral vein in two subjects.
A sub-analysis looking at complications and operator experience suggests the SADE rate “would be expected to improve with increased operator experience,” noted Dr. Reddy.
“With the exception of one operator, none of the other operators in this trial had any prior clinical experience with implantation of the device.”
When cases were stratified according to the first 10 devices implanted versus subsequent implants by the same operator, the procedural SADE, device dislodgement, and cardiac perforation rates changed from 6.8% to 3.6% (P=0.6), 1.3% to 0.0% (P=0.9), and 1.5% to 1.8% (P=0.6), respectively.
“These multicenter data represent the largest population of patients to receive a leadless pacemaker system and as such provide unique insight into their efficacy and safety,” concluded Dr. Reddy.
“When interpreted in the context of limited prior experience of the majority of operators with this new technology, these results provide support for the applicability of this technology in routine clinical practice.”
The device received CE Mark in 2013.
SOURCES OF FUNDING: The study was sponsored by St. Jude Medical Inc., which manufactures the device.
DISCLOSURES: Dr. Reddy serves at the Chair of the Steering Committee for the LEADLESS II trial, and has received consulting fees from St Jude Medical (the manufacturer of the pacemaker in the study)
ESC Press OfficeFor background information or assistance, please contact the ESC Press Office.For independent comment on site or interviews, please contact the ESC spokesperson coordinator: +44 7785 467 947
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2015ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. More information is available from the ESC Press Office at email@example.com.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2015. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved